Research

Many clinical trial results not shared, creating 'blind spot'

Less than 40% of the results of clinical trials conducted at leading academic medical centers were shared within two years of completion, Yale School of Medicine researchers report in a new study published in the current issue of the British Medical Journal.

"Not only was performance poor, but there was significant variation across the academic medical centers we studied," said Dr. Nihar Desai, assistant professor of medicine, section of cardiology at Yale School of Medicine and a researcher at the Yale Center for Outcomes Research and Evaluation.

Desai said randomized clinical trials are the gold standard in terms of testing the efficacy and safety of drugs, devices, and treatment strategies, so disseminating the results is of vital importance.

"Researchers also have an ethical responsibility to the patients enrolled in the study to make the results available," he said. "Providers and patients will never be able to make evidence-based health care decisions if the data is not in the public domain. In addition, future research cannot benefit from what other researchers have already done if results are not reported and/or published in a timely fashion."

Desai and his co-authors previously studied the rates of results reporting and publication of clinical trials sponsored by the National Institutes of Health and by pharmaceutical companies. They decided to extend that prior work by looking at the dissemination of clinical trial results across leading academic institutions. The team reviewed over 4,300 clinical trials and examined how many were published or had results reported on ClinicalTrials.gov within 24 months of the studies' completion.

The team saw a three-fold variation in performance, with some institutions disseminating 16% of their completed clinical research, while others disseminated 55%.

"This is yet another blind spot in the clinical research enterprise, and we hope our findings will serve as a call to action," said Desai. "Academic medical centers are uniquely positioned to lead this effort. They are dedicated to generating knowledge to improve health and health care. We hope our study will lead to a renewed commitment to our professional values and the mission of academic centers to not only conduct rigorous scientific investigation, but to share the results in a timely and transparent fashion."

Other authors on the study included first author Ruijun Chen, Joseph S. Ross, Weiwei Zhang, Katherine H. Chau, Brian Wayda, Karthik Murugiah, Daniel L. Lu, Amit Mittal, and senior author Harlan M. Krumholz.

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Diabetes drug may also offer vascul…

Obesity and Type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease. Obese and diabetic premenopausal women are most at risk...

Read more

Intestinal flora effects drug respo…

Intestinal flora has multiple influences on human health, but researchers have revealed that it is also likely to have an effect on the body's response to drugs. Recent r...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016